亚铵制浆黑液非无菌操作连续发酵生产酵母

从土壤中筛选出能在亚铵黑液中生长的毕赤酵母菌株（Ｐｉｃｈｉａ ｓｐ．Ｎｏ．１）经耐毒驯化后，可接种于酸析脱木素和汽提脱毒后的亚铵黑液中，在非无菌操作条件下连续发酵生产酵母菌体，该菌生产迅速，连续培养衡释率达０．２６ｈ＾－１，总糖的酵母得率为０．４８ｇ／ｇ（ＴＳ），ＣＯＤ去除２３％，菌体易絮凝，可自然沉降分离。     

山东省森林资源与木材供需平衡模型的建立与应用

本文在对山东省森林资源和木材供需平衡状况进行系统分析的基础上，利用系统动力学方法建立了山东省森林资源与木材供需平衡模型，通过对不同方案的政策仿真和结果分析，试图提出解决山东省木材供需矛盾的最佳途径，为制定林业发展政策提供依据。     

Prenatal diagnosis of Freeman–Sheldon syndrome (whistling face)

The diagnosis of Freeman–Sheldon syndrome was made by ultrasonographic evaluation of a 20-week fetus with a positive family history. The ultrasonographic features were abnormalities of the extremities and mouth.     

海水烟气脱硫初探

分析了金山卫，定海，北仑港和台州等地的海水成份，测定了它们的缓冲能力，在鼓泡反应器中进行了海水吸收ＳＯ２的静态试验和使吸收液中ＳＯ３＾２－转变为ＳＯ４＾２－的氧化试验，试验结果表明海水具有用作烟气脱硫吸收液的可能性和吸收液经曝气后直接排海的可能性。     

重庆大气可吸入颗粒物中多环芳烃的分析测定

本文报告了重庆大气可吸入颗粒物(IP)中多环芳烃(PAH)的分析测定方法和结果.用GC-MS定性和定量分析了重庆IP中的PAH;研究了IP中PAH的种类和分布情况;确认重庆IP中存在甲基多环芳烃(MePAH)、约占33%;颗粒大小分布表明,约有98%PAH存在于小于3μm的颗粒中.     

Second-trimester cancer antigen 125 and Down's syndrome

This study explores if assay of cancer antigen 125 (CA 125) in maternal serum might aid the detection of Down's syndrome in the second trimester of pregnancy. CA 125 levels were determined retrospectively in stored maternal serum samples from ten Down's syndrome pregnancies and 78 controls matched for gestational and maternal age. In addition, second-trimester amniotic fluid samples from nine Down's syndrome and 109 unaffected pregnancies were analysed for CA 125. Maternal serum CA 125 values for Down's syndrome pregnancies were lower, with the median being 0.72 multiples of the unaffected population median. The medians for affected and unaffected pregnancies did not differ significantly and there was a considerable overlap in the range of values of cases and controls. The distribution of amniotic fluid CA 125 levels for Down's syndrome pregnancies resembled that for controls. From our present results, we could not find an association between Down's syndrome and second-trimester maternal serum or amniotic fluid CA 125 levels.     

Study on nitrile-degrading microorganisms

Two strains of bacteria were isolated from nitrile polluted soils, and identified as Corynebacterium boffmanii and Arthrobacter flavescens. Acetonitrile, propionitrile, butyronitrile and acrylonitrile were degraded by these bacteria to yield corresponding amides, carboxylic acids and ammonia. The nitrile-degrading abilities of these strains were investigated. The removal rates for the nitrile were nearly 100%, after these bacteria were grown in medium containing 10000 ppm of aceto-, propio-, or butyronitrile at 28 ℃ for 24h. When the reaction mkture consisting of 5000 ppm of above mentioned nitriles or acrylonitrile and 20g (dry cell) /L resting cells of the two strains in 0.06mol/L phosphate buffer (pH7.5) was incubated separately at 25 ℃ with moderate shaking for 15 or 45 min, the nitrile could be degraded completely. The optimum growth conditions for C.hoffmanii and A.flavescens were studied as well.     

Extraction of DNA from amniotic fluid cells for the early prenatal diagnosis of genetic disease

Ten-ml samples of amniotic fluid were taken from pregnancies being terminated at 8–14 weeks' gestation. DNA was extracted from the amniotic cells by sequential centrifugation and analysed using the polymerase chain reaction (PCR). Fifteen samples were analysed for evidence of maternal contamination using Mfd5 oligo-nucleotide primers for repeat polymorphisms. Ten amniotic fluid samples were tested for the Delta-F₅₀₈ deletion characteristic of cystic fibrosis to demonstrate a diagnostic application for the technique. In each case, DNA extracted from fetal tissue from the same pregnancy was included in the controls. In 14 of the 15 cases tested with the Mfd5 primers, both the amniotic fluid DNA and the fetal DNA showed no evidence of contaminating DNA. In one case, neither the amniotic fluid cells nor the fetal cells yielded results. In nine of the ten cases tested with the Delta-F₅₀₈ primers, the amniotic fluid cell DNA provided accurate information about the genetic status of the fetus; in the tenth, the fetal DNA failed to amplify. The results indicate that adequate DNA can be extracted from amniotic fluid from 8 weeks' gestation onward and these samples are suitable for prenatal diagnosis using PCR.     

Vitamins,folic acid and neural tube defects: Comments on investigations in the United States

No clear answer concerning whether multivitamin/folate supplementation prevents neural tube defects (NTDs) is provided by three studies in the United States. All these studies are occurrence in nature, no recurrence studies having been conducted. The Atlanta Birth Defects Study is subject to pronounced memory and recall biases, the length between event and interview being as long as 16 years. In a second study (Boston University), objections can be raised to certain aspects of the experimental design, and the claim that 22 per cent of women started vitamins sufficiently early after pregnancy diagnosis to influence NTD formation is suspicious. Our NICHD case control study of 541 women in California and Illinois revealed no evidence for multivitamins or folic acid preventing NTDs. U.S. public policy-makers face difficulties in applying results of recurrence or occurrence studies in high-risk areas to low-risk areas in the U.S.     

Prenatal screening and diagnosis of neural tube defects in England and Wales in 1985

A survey was carried out to determine the effect of prenatal screening and therapeutic abortion on births in 1985 with anencephaly and spina bifida in England and Wales. Maternal serum alpha-fetoprotein tests were done on 399 288 women (60 per cent of pregnant women): 4 per cent were reported as being screen-positive and 1 per cent had an amniocentesis. An estimated 534 pregnancies associated with anencephaly were terminated and an estimated 445 pregnancies associated with spina bifida (but without anencephaly) were terminated. Most (63 per cent) of the anencephalic pregnancies were first suspected from an ultrasound examination; 57 per cent of the spina bifida pregnancies were first suspected from a positive maternal serum alpha-fetoprotein test, 35 per cent by ultrasound, and the remaining 8 per cent by other means. The birth prevalence of anencephaly declined by 94 per cent between 1964–1972 and 1985, but when the terminations of pregnancy on account of having a fetus with anencephaly are added to the births the decline in prevalence was only 50 per cent. The birth prevalence of spina bifida declined by 68 per cent over the same period but when the terminations were added to the births the decline in prevalence was only 32 per cent. Among births with anencephaly 66 per cent had had no screening or diagnostic tests in early pregnancy, but in those that did nearly all were positive–usually in twin pregnancies where one fetus was affected but not the other. Among births with spina bifida, 48 per cent had no tests and in those that did the results were mainly negative. We conclude that in order to monitor adequately the national screening programme for anencephaly and spina bifida a special neural tube defects register should be formed.